| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/24/2002 | CA2415896A1 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/24/2002 | CA2415894A1 Activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/24/2002 | CA2415882A1 Composition for topically delivering vitamin c |
| 01/24/2002 | CA2415751A1 Masp-2, a complement-fixing enzyme, and uses for it |
| 01/24/2002 | CA2415712A1 Protein complex serving as a vehicle for orally administerable medicaments |
| 01/24/2002 | CA2415697A1 Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| 01/24/2002 | CA2415690A1 Tetraspan protein and uses thereof |
| 01/24/2002 | CA2415678A1 Amino alcohol derivatives |
| 01/24/2002 | CA2415673A1 Tetrazole derivatives |
| 01/24/2002 | CA2415665A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | CA2415557A1 Compounds for the treatment of sexual dysfunction |
| 01/24/2002 | CA2415331A1 Beta3 adrenergic agonists |
| 01/24/2002 | CA2415325A1 Preventing airway mucus production by administration of egf-r antagonists |
| 01/24/2002 | CA2415285A1 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds |
| 01/24/2002 | CA2415128A1 An implantable or insertable therapeutic agent delivery device |
| 01/24/2002 | CA2415126A1 Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
| 01/24/2002 | CA2414783A1 Treatment of eating disorders using carboxyalkylethers |
| 01/24/2002 | CA2414780A1 Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
| 01/24/2002 | CA2414674A1 Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| 01/24/2002 | CA2414407A1 Stabilized 1.alpha.-hydroxy vitamin d |
| 01/24/2002 | CA2413582A1 Use of a spla2 inhibitor for the treatment of sepsis |
| 01/24/2002 | CA2391791A1 Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence |
| 01/24/2002 | CA2386794A1 Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics |
| 01/24/2002 | CA2384765A1 Health food useful for preventing liver and biliary dysfunctions containing an alkanoyl l-carnitine and silybum marianum extract |
| 01/24/2002 | CA2384041A1 Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| 01/23/2002 | EP1174514A1 Recombinant influenza viruses with bicistronic vRNAs coding for two genes in tandem arrangement |
| 01/23/2002 | EP1174438A1 Novel cyclic tetrapeptide derivatives and use thereof as drugs |
| 01/23/2002 | EP1174431A2 2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors |
| 01/23/2002 | EP1174427A1 Method for pulvirizing to fine powder |
| 01/23/2002 | EP1174423A1 Substrates for thioredoxin reductase |
| 01/23/2002 | EP1174416A1 Conjugated fatty acid esters |
| 01/23/2002 | EP1174151A1 Preventive or therapeutic drugs for various eosinophilia-related diseases containing chymase inhibitors as the active ingredient |
| 01/23/2002 | EP1174150A1 Preventives/remedies for angiostenosis |
| 01/23/2002 | EP1174149A1 Proliferation inhibitor for androgen-independent tumor |
| 01/23/2002 | EP1174142A2 Immunopotentiator comprising peptide and hyaluronic acid |
| 01/23/2002 | EP1174141A2 Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes |
| 01/23/2002 | EP1174140A1 Skin preparations for external use |
| 01/23/2002 | EP1174139A2 Use of mometasone furoate for treating airway passage and lung diseases |
| 01/23/2002 | EP1174138A2 Use of mometasone furoate for treating airway passage and lung diseases |
| 01/23/2002 | EP1174137A1 Patches containing buprenorphine hydrochloride |
| 01/23/2002 | EP1174136A2 Oral pharmaceutical dosage form containing a proton pump inhibitor |
| 01/23/2002 | EP1174135A2 Pharmaceutical composition for use in treatment of diabetes |
| 01/23/2002 | EP1174134A1 Compositions for treating brain infarction |
| 01/23/2002 | EP1174133A1 Pharmaceutical compositions containing amorphous mupirocin |
| 01/23/2002 | EP1174132A1 Percutaneous absorption preparations containing oxybutynin |
| 01/23/2002 | EP1174131A1 Agent for treating parkinson's disease comprising astrocyte function-improving agent as active ingredient |
| 01/23/2002 | EP1174130A2 Use of preparations of curcuma plants |
| 01/23/2002 | EP1174129A1 Use of a matrix-metalloprotease inhibitor for the treatment of cancer |
| 01/23/2002 | EP1174128A1 Vitamin-C preparation and process for preparation thereof |
| 01/23/2002 | EP1174126A1 Antibody and polyalkylene glycol-bonded liposome |
| 01/23/2002 | EP1174125A1 Intraocular infusion solution |
| 01/23/2002 | EP1174118A1 Use of inulin and derivatives thereof |
| 01/23/2002 | EP1174109A2 Combinations of active substances respectively adducts from cyclodextrins and at least a quinone and/or at least a hydroquinone and use of such combinations of active substances in cosmetic preparations |
| 01/23/2002 | EP1173767A1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
| 01/23/2002 | EP1173757A1 Diagnosis of human kidney diseases |
| 01/23/2002 | EP1173600A2 Cationic peg-lipids and methods of use |
| 01/23/2002 | EP1173571A2 Human ion channel proteins |
| 01/23/2002 | EP1173566A2 Human membrane-associated proteins |
| 01/23/2002 | EP1173563A1 Compositions and methods for the treatment of tumour |
| 01/23/2002 | EP1173562A2 Inhibition of histone deacetylase |
| 01/23/2002 | EP1173561A2 Non-invasive method for detecting target rna |
| 01/23/2002 | EP1173521A1 Stable, aqueous dispersions and stable, water-dispersible dry powders of xanthophylls, and production and use of the same |
| 01/23/2002 | EP1173517A1 In situ forming hydrogels |
| 01/23/2002 | EP1173479A1 49 human secreted proteins |
| 01/23/2002 | EP1173478A1 49 human secreted proteins |
| 01/23/2002 | EP1173468A1 Integrin receptor antagonists |
| 01/23/2002 | EP1173464A2 Process of purifying phytosterols from wood or plant-derived sources by means of metal salt complexes and compositions resulting therefrom |
| 01/23/2002 | EP1173455A2 Novel ribose-substituted aromatic amides, method for the production and use thereof as medicaments |
| 01/23/2002 | EP1173454A1 Method for producing glyco-conjugates of 20(s)-camptothecin |
| 01/23/2002 | EP1173451A1 New antioxidative vitamin b 6 analogs |
| 01/23/2002 | EP1173443A1 Cyclic urea and cyclic amide derivatives |
| 01/23/2002 | EP1173441A1 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
| 01/23/2002 | EP1173440A1 Tetracyclic azepinoindole compounds as 5-ht receptor ligands |
| 01/23/2002 | EP1173439A1 Haloalkoxy imidazonaphthyridines |
| 01/23/2002 | EP1173438A1 Substituted imidazoles, their preparation and use |
| 01/23/2002 | EP1173437A2 Thiazolidinedione derivative and its use as antidiabetic |
| 01/23/2002 | EP1173436A2 Thiazolidinedione derivative and its use as antidiabetic |
| 01/23/2002 | EP1173435A1 Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt |
| 01/23/2002 | EP1173434A2 Thiazolidinedione derivative and its use as antidiabetic |
| 01/23/2002 | EP1173433A1 Cyanopyrroles as progesterone receptor agonists |
| 01/23/2002 | EP1173432A1 Piperidine-indole compounds having 5-ht6 affinity |
| 01/23/2002 | EP1173431A2 Method for the preparation of citalopram |
| 01/23/2002 | EP1173429A1 Protease inhibitors |
| 01/23/2002 | EP1173427A1 Hydroxamic acid derivative |
| 01/23/2002 | EP1173426A1 Cyclocarbamate derivatives as progesterone receptor modulators |
| 01/23/2002 | EP1173424A1 Pyrimidine compounds |
| 01/23/2002 | EP1173423A1 Benzimidazolones and analogues and their use as progesterone receptor ligands |
| 01/23/2002 | EP1173422A1 Bis-benzazoles and their use as antineoplastic agents |
| 01/23/2002 | EP1173421A2 Indole derivatives as anti-inflammation agents |
| 01/23/2002 | EP1173420A2 Heterocyclic compounds having antitumor activity |
| 01/23/2002 | EP1173418A1 Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide |
| 01/23/2002 | EP1173415A1 Diphenylurea derivatives |
| 01/23/2002 | EP1173414A1 N-protected amines and their use as prodrugs |
| 01/23/2002 | EP1173408A1 Ppar-(gamma) agonists as agents for the treatment of type ii diabetes |
| 01/23/2002 | EP1173403A1 Salts of asiatic and madecassic acid suitable for the preparation of pharmaceutical and cosmetic compositions |
| 01/23/2002 | EP1173255A2 Use of pirenoxine for the protection of corneal tissues in photokeratectomy |
| 01/23/2002 | EP1173254A2 Novel treatment of neurotraumatic conditions with a raf inhibitor |
| 01/23/2002 | EP1173253A1 Contraceptive compositions containing cyclic carbamates and amide derivatives |
| 01/23/2002 | EP1173244A1 Powder inhaler for combined medicament |
| 01/23/2002 | EP1173224A1 Polyethyleneimine:dna formulations for aerosol delivery |